GERD (K21.9) develops when the lower esophageal sphincter relaxes inappropriately or is mechanically weakened, allowing acid and other gastric contents to contact the esophageal mucosa. Symptoms two or more times weekly, or visible mucosal injury, separate disease from ordinary occasional reflux. [9] Obesity and smoking, including secondhand smoke, raise risk and worsen exposure. Anxiety and depression are also associated with higher reflux risk, so symptom burden should be screened alongside acid control. [2]
Proton pump inhibitors remain the backbone of therapy. Typical dosing is omeprazole 20 mg or esomeprazole 20–40 mg once daily, 30–60 minutes before the first meal, for 4–8 weeks of healing. A meta-analysis comparing the two found a modest healing advantage for esomeprazole. [8] When symptoms persist despite adherent PPI use, vonoprazan, a potassium-competitive acid blocker, has meta-analytic evidence of efficacy in PPI-resistant disease. [5]
Adjunctive strategies matter. Alginate therapy, which forms a floating gel raft over gastric contents, improved GERD symptoms versus control in a systematic review. [3] Dietary interventions show benefit in pooled intervention studies. [4] Physical activity has been examined as a risk modifier, with the relationship depending on intensity. [6] Helicobacter pylori status should be handled on its own indications, since eradication has a variable relationship with reflux. [7]